Clinical Profile of Patients With Pulmonary Hypertension Due to Lung Diseases ( Single Center Experience)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02774928|
Recruitment Status : Recruiting
First Posted : May 17, 2016
Last Update Posted : July 12, 2016
Development of pulmonary hypertension (PH) in chronic lung diseases has both functional and prognostic implications .
PH in Lung diseases is usually mild to moderate with preserved cardiac output, and evolves slowly alongside the progression of lung disease and hypoxemia .
However, a minority of patients develop severe PH with elevations in pulmonary artery pressure that have been described as ''out of proportion'' to the underlying disease .
The aim of this study is to compare the characteristics and outcomes of consecutive patients with PH-due to lung diseases diagnosed at our specialist referral center over a 1-year period.
|Condition or disease|
Show Detailed Description
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||150 participants|
|Target Follow-Up Duration:||1 Year|
|Official Title:||Clinical Profile of Patients With Pulmonary Hypertension Due to Lung Diseases ( Single Center Experience)|
|Study Start Date :||June 2016|
|Estimated Primary Completion Date :||May 2017|
|Estimated Study Completion Date :||May 2017|
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality throughout the world.COPD, a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.Spirometry is required to make a clinical diagnosis of COPD; the presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation and thus of COPD .
Interstitial lung diseases
Interstitial lung disease is a general category that includes many different lung conditions. All interstitial lung diseases affect the interstitium, a part of the lungs' anatomic structure.
Obstructive sleep apnea (OSA)
Obstructive sleep apnea (OSA) is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing and is characterized by recurrent episodes of upper airway collapse during sleep.
These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.
OSA that is associated with excessive daytime sleepiness is commonly called obstructive sleep apnea syndrome—also referred to as obstructive sleep apnea-hypopnea syndrome.
- prevalence of PH [ Time Frame: 1 year ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02774928
|Contact: Mostafa I Elshazly, MDfirstname.lastname@example.org|
|Cairo, Egypt, 12411|
|Contact: Mostafa I Elshazly, MD 00201001272020 email@example.com|
|Sub-Investigator: Hebatallah H Assel, MD|
|Sub-Investigator: Amira I Alameldin, MD|
|Sub-Investigator: Reem Elkorashy, MD|
|Sub-Investigator: Eman Kamal, MD|
|Sub-Investigator: Naglaa Bakry, MD|
|Principal Investigator:||Mostafa I Elshazly, MD||Kasr Alaini school of Medicine|
|Study Director:||Yusif Amin, MD||Kasr Alaini school of Medicine|